Aurinia (AUPH) SVP has 8,069 shares withheld for taxes

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan had 8,069 shares of Common Stock withheld on March 6, 2026 to cover tax obligations when restricted stock units vested. These shares were valued at $14.32 per share for this tax-withholding calculation. After this routine withholding, Keenan directly holds 154,449 common shares, showing he maintains a substantial equity position in the company.

Insights

Equity compensation and insider-transactions analyst

Routine tax withholding on RSU vesting; no open-market sale or strong signal.

The Form 4 shows 8,069 shares of Aurinia Pharmaceuticals common stock withheld on March 6, 2026 at $14.32 per share. The F code and footnote explain this was to satisfy tax obligations upon the vesting of restricted stock units, not a discretionary sale.

This type of transaction is a common, mechanical feature of equity compensation plans. It does not indicate a change in sentiment because the insider did not choose to sell shares in the market. After the withholding, Keenan still directly owns 154,449 shares, so the disposition is small relative to his remaining stake.

Given its compensation-related nature and modest scale versus ongoing holdings, this event is best viewed as administrative rather than a thesis-changing development. Subsequent filings may provide additional context on future grants or vesting events, but this specific transaction is neutral in isolation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keenan Greg

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		F		8,069(1)	D	$14.32	154,449	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

Remarks:

	/s/ Greg Keenan, M.D.	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aurinia Pharmaceuticals (AUPH) report for Greg Keenan?

Aurinia Pharmaceuticals reported that SVP and Chief Medical Officer Greg Keenan had shares withheld to cover taxes on vested restricted stock units. On March 6, 2026, 8,069 common shares were used to satisfy tax obligations, rather than being sold in the open market.

How many Aurinia (AUPH) shares were withheld for Greg Keenan’s tax obligations?

The filing shows 8,069 shares of Aurinia common stock were withheld to meet tax withholding obligations when restricted stock units vested. The withholding price used was $14.32 per share, reflecting the value applied to calculate the tax due on the vesting event.

Was Greg Keenan’s Aurinia (AUPH) transaction an open-market share sale?

No, the transaction was not an open-market sale. It was coded as an F transaction, with a footnote stating the 8,069 shares represented withholding to satisfy tax obligations upon RSU vesting, a routine administrative step in equity compensation rather than a discretionary sale.

How many Aurinia (AUPH) shares does Greg Keenan hold after this Form 4 transaction?

After the tax-withholding disposition, Greg Keenan directly holds 154,449 shares of Aurinia common stock. This remaining position indicates the withheld 8,069 shares represent only a small portion of his overall holdings, reinforcing that the event is routine and compensation-related.

What does the F transaction code mean in the Aurinia (AUPH) Form 4 for Greg Keenan?

The F code indicates a tax-withholding disposition, where shares are delivered to cover exercise price or tax liabilities. In this case, 8,069 shares were withheld to satisfy tax obligations on vesting restricted stock units, rather than being voluntarily sold into the market.